Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| In addition, over the long term, we continue to see strong opportunity for kits gross margins to improve as we increase our own content on the platform |
| Olin saw continued success on business momentum in the second quarter |
| So, we are very excited about that and sort of how that will sort of improve sort of margins on the service side as we consider sort of the second half of the year, in particular, sort of the 2024 and beyond |
| Overall, we continue to make expected and solid progress on all major strategic objectives |
| And I think that's being recognized by our customers, which is a really positive statement in terms of, again, customer reception |
| Explore 1536 and Explore 3072 were both incredible innovations that helped launch the next-generation proteomics market, while also laying the foundation for Olink's leadership |
| So, so far, again, in the context of what I stated in terms of pricing and then total cost per experiment, the product is being received extremely well |
| So again, overall, we feel very positive and HT is most definitely a part of that optimism, especially sort of the early signals that we're getting just in this past month |
| And we think that we're in good shape for the second half of the year |
| So, we remain really positive on the outlook for the mid-plex business as well |
| So, we're continuing to see positive effects of growing that installed base of Signature instruments |
| We had good kit growth, again, as noted in Q2 |
| We expect that Explore HT will help further cement our market-leading position by demonstrating our commitment to high-quality products and innovation |
| In software and our data ecosystem, we also made strong progress with Olink Insight by significantly expanded its normal ranges resource with data from 2 large cohorts |
| We have a very strong pipeline going forward |
| As Olink Insight's users base and data pool both expand over time, its value will increase dramatically for customers within the Olink ecosystem and can be further enhanced through advanced data techniques like machine learning and algorithmic approaches |
| So, we're really happy with that |
| Today, less than a year from that impressive achievement, we've exceeded 1,300 and expect to see the rate of strong scientific productivity to continue |
| Carl Raimond Yes, no, we're very happy with the placements in Q2, met expectations for the first half, really tremendous |
| We believe Olink's culture of ceaseless innovation has yielded the industry's broadest and most well-positioned product portfolio today, across high to low-plex and with end-to-end workflow solutions |
| The engine of Olink's success is stronger than ever, and we look to the future with even greater optimism |
| Being able to contemplate now a study on the scale of 500,000 to 1 million samples with the kind of throughput that we can do now is incredible to consider in how short a period of time that can now be executed, which is, I think, a very exciting proposition for the market |
| So yes, it's very, very impressive |
| It was another strong quarter for Explore externalizations with 11 new sites, and the total reaching 74 at the end of June |
| But otherwise, I mean, just fundamentally, yes, we have a fantastic team that's executing very well, I think is really the statement |
| They've been executing extremely well |
| Geographic highlights included very strong performance from APAC led by China and Japan, with APAC revenue nearly doubling year-over-year |
| Trends in the base business improved from the first quarter |
| On the question of China, yes, I mean, obviously, when you compare us to many others likely -- I mean, we obviously start from smaller starting points in terms of dollar revenues, right? So, we are extremely impressed about our Chinese team and their success in the market |
| The aggregate results on our revenue was that several late-quarter orders were pushed into the second half of the year, particularly in the Americas, where year-over-year growth in the region is expected to rebound strongly in Q3 |
| Statement |
|---|
| In addition, while reported revenue growth in EMEA was negative in Q2 once again, due largely to the high plex biopharma market |
| Throughout this quarter, China has been a pain point |
| We navigated through a challenging external operating environment, which, in combination with our new product launch, pushed our revenue seasonality to be more back-half weighted as indicated earlier in the year |
| In addition, we reported adjusted EBITDA of negative $11.6 million versus negative $7.9 million in second quarter of 2022 |
| So again, and as I noted, the headwinds that even sort of you've heard and our peer groups talk about in the biopharma segment, there's pockets of headwinds is may be a good way to describe it because you can't paint all accounts with the same brush |
| Now proteins in health individuals is a critical biological problem |
| And then on the -- it seems like from your opening comments, the academic end market clearly is holding up in the challenging macro compared to the biopharma customer segment |
| The result has been an increase in deal friction that has lengthened our sales cycle and impacted timing of customer purchases, which has been compounded by customer anticipation of the recently launched Explore HT |
| Customer activity, more notably with biopharma customers, continued to be impacted by the macroeconomic environment, which we previously cited |
| Second quarter kit mix was 36% of total revenue versus 26% a year ago and down sequentially from Q1 2023 |
| And we've considered, of course, as noted in the commentary some of those macro headwinds that exist out there |
| Average pull-through number is something we often discuss together, right? And it's very difficult to predict |
| This pull-through remains healthy and the sequential quarterly decline was driven in part by the expected lower kit mix in Q2 versus Q1 of this year |
| Net loss for the second quarter was $8.3 million as compared to a net loss of $4.8 million for the second quarter of 2022, while net loss per share was $0.07 as compared to a net loss per share of $0.04 for the second quarter 2022 |
| Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors |
| The question, what does normal look like? It's a fundamental one that remains largely unanswered |
| So yes, as noted in that second half outlook and our sort of full-year guide, yes, we've sort of -- the optimism for Explore HT, I mean, we knew it was going to be a big hit |
| Again, we launched less than a month ago really, but all of those conversations have now been and are being reengaged in light of a very significant product introduction here |
Please consider a small donation if you think this website provides you with relevant information